La société est consacrée au développement d'une nouvelle classe de biomédicament: les anti-angiogéniques de deuxième génération
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free